non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Surgical Intervention

  • Further studies are needed to support use of bone marrow transplant (BMT) & stem cell transplant (SCT) in high-risk NHL patients
Bone Marrow Transplant (BMT)
  • Treatment of choice for patients with aggressive recurrent NHL
  • Studies show improved survival (20-40% long-term disease free rate) in high-risk patients
Stem Cell Transplantation (SCT)
  • May be considered in patients with indolent recurrent NHL, & aggressive noncontiguous stage II/III/IV NHL
    • Studies show an increase in the progression-free survival rate of patients given SCT as compared to those given chemotherapy alone
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.

01 Dec 2015
Colchine use in male Taiwanese patients with gout is associated with substantially reduced risk for cancer, as shown in a 12-year cohort study.